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Surgery for Recurrent 
Glioblastoma
Vamsi Krishna Yerramneni, Ramanadha Reddy Kanala, 
Vasundhara S. Rangan and Thirumal Yerragunta
Abstract
Recurrence of glioblastoma (GB) is inevitable. As the optimal management 
for recurrent glioblastoma continues to evolve, clear treatment guidelines for are 
lacking. Existing literature does not clarify the role that second surgery plays in 
the treatment of these patients. Although few studies report that second surgery is 
beneficial in select patients and leads to longer overall survival (OS), other stud-
ies have demonstrated the limited impact that repeat surgery has on the eventual 
patient outcome. Maximal safe resection (high extent of resection—EOR) has been 
proven to improve the OS at reoperation, even when undertaken for cases where the 
first surgery achieved only a limited EOR. Karnofsky Performance Score (KPS) and 
age at presentation are valuable prognostic factors that predict better OS and aid 
in better patient selection for surgical management. The true value of reoperation 
versus systemic treatment, their effects the patient’s QoL and the added increase in 
overall survival is better judged after detailed investigation by means of a prospec-
tive, randomized trial.
Keywords: EOR—extent of resection, KPS—Karnofsky Performance Score,  
rGB—recurrent glioblastoma
1. Introduction
Glioblastoma (GB) is not only the most common primary intrinsic brain tumor 
of adulthood, but also the most frequently encountered malignant subtype. The 
standard treatment for newly diagnosed GB remains maximal surgical resection 
followed by concomitant or adjuvant chemotherapy [1]. The culmination of all the 
developments in diagnostics, imaging, surgical refinements and adjuvant therapies 
has not translated into any significant boost to the median overall survival (OS) 
of these patients. Prognosis continues to be dismal and OS has risen by just about 
3.3 months (from 11.3 to 14.6 months) [2]. In select cohorts (consisting of a very 
favorable subset of patients), a median OS of 20.5 months has been observed. 
Recurrence is inevitable in GB despite every kind of known therapy. The standard 
care of the recurrent GB (rGB) is incompletely defined. Considering the ineffective-
ness of therapy for first time disease, patients with recurrent disease are left with 
even more limited truly useful treatment options. With no clear standard of care, 
available options include reexcision of the lesion, angiogenesis inhibitor agents, and 
other targeted therapies, some of which have been the subject of clinical trials. In 
current practice, second surgery is performed in less than one half of the patients 
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who present with rGB. This might be either due to a seemingly inoperability of the 
lesion or poor surgical fitness of the patient [3, 4]. Several studies and reviews are 
published, but undertaking extensive surgery in the recurrence of a disease defined 
by poor prognosis continues to remain controversial.
2. Criteria for diagnosis of recurrent GB
Criteria for diagnosis have undergone many modifications over past decade. 
Magnetic resonance imaging every 2–3 months remains the gold standard for 
assessment of response and progression of the GB. The Macdonald criteria have 
served as the standard tool in follow up and evaluation of this disease until 
2010 and their widespread use has led to the observation of several shortcom-
ings [5, 6]. These include the problem of measuring tumor deposits shaped 
irregularly (including tumor forming the lining of cystic or excision cavities), 
observer to observer variability, lack of guidance for the evaluation of multifo-
cal tumors as well as non-enhancing portion(s) of the tumor [5, 6]. Wen et al. 
published updated criteria in 2010 with restricted parameters for diagnosis of 
progressive disease within 3 months after completion of adjuvant therapy and 
integration of the evaluation of T2/FLAIR sequences as well of corticosteroid 
use [6].
According to the Macdonald et al. [5] criteria, progression of the tumor is 
defined as development of one or more of the following features:
“25% increase in sum of the products of perpendicular diameters of enhancing 
lesions, development of any new lesion on imaging and/or clinical deterioration.”
The lack of specificity of enhancement in GB patients treated with surgery, 
radiation or chemotherapy as well as other difficulties in standardization of assess-
ment by the above criteria led to the need for updated Response Assessment in 
Neurooncology group (RANO) criteria. These criteria define progression as pres-
ence of any one of the following:
“≥25% increase in sum of the products of perpendicular diameters of 
enhancing lesions compared with the smallest tumor measurement obtained 
either at baseline (if no decrease) or best response, on stable or increasing doses 
of corticosteroids; significant increase in T2/FLAIR nonenhancing lesion on 
stable or increasing doses of corticosteroids compared with baseline scan or best 
response after initiation of therapy not caused by comorbid events (e.g., radia-
tion therapy, demyelination, ischemic injury, infection, seizures, postoperative 
changes, or other treatment effects); any new lesion; clear clinical deterioration 
not attributable to other causes apart from the tumor (e.g., seizures, medication 
adverse effects, complications of therapy, cerebrovascular events, infection, 
and so on) or changes in corticosteroid dose; failure to return for evaluation as 
a result of death or deteriorating condition; or clear progression of nonmeasur-
able disease.”
Figure 1 is an example of recurrent GBM managed by surgery followed by 
Bevacizumab chemotherapy.
3. Indications of surgery
Surgery is indicated in patients who show both:
1. Progression of disease according to MacDonald or RANO radiological criteria.
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2. Deterioration in clinical status (as manifested by development of new deficits, 
change in neurological status due to mass effect of the lesion, seizures, or, 
features of raised intracranial pressure).
The decision to undertake repeat surgery is especially valid in young patients, 
patients with good functional status and a conveniently resectable tumor.
In rGB, surgery is undertaken with the main aim of cytoreduction. The reduced 
tumor burden is thought to cause an improvement in OS [7, 8]. Lu et al. in their 
meta-analysis concluded that repeat surgery has an overall positive role in managing 
recurrent GBM. It was observed that surgery resulted in a prognostic benefit that was 
observed to be independent of demographic as well as clinical parameters [8]. Various 
factors which are found to affect prognosis are age, extent of resection at repeat 
surgery, adjuvant chemoradiation, tumor location, methylation status, in addition to 
Figure 1. 
(1a–1d) MRI brain T2 Axial, Axial FLAIR, Axial contrast and sagittal contrast images showing Right 
ParietoOcciptial mass with surrounding edema with corresponding enhancement on the contrast. Surgical 
excision of the tumor was done with around 60% excision followed by chemoradiotherapy as per Stupp 
Protocol. (2a–2d) One year after the initial treatment patient follow up MRI (2a–d) shows Tumor regrowth. 
Patient was taken up for Redo surgical excision and around 70% of the tumor excision was achieved. After 
second surgery patient was treated in another center with bevacizumab and he came back to us in 3 months 
with regrowth of the tumor. (3a–3d) Patient had low platelet count as a result of the bevacizumab therapy 
and was in poor general condition. Surgery excision was not considered as the outcome in patients with 
poor performance score in recurrent tumor is bad though the MRI does not show an extensive tumor. Poor 
performance scores with a not so extensive gross tumor on MRI indicate microscopic infiltration.
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functional assessment of the patient using scores like Karnofsky Performance Status 
(KPS) and Eastern Cooperative Oncology Group (ECOG) score. Nonetheless, studies 
conducted that have analyzed patient groups after matching for many of these factors 
have still observed the prognostic advantage conferred by surgery undertaken for 
recurrent disease. The potential benefit is not limited to the first recurrence only. 
Superior OS in patients with GB experiencing more repeat surgeries for continuously 
recurring GB independent of other features has been previously shown [9, 10].
Various factors have been analyzed with respect to surgery in recurrent GB:
3.1 Age
Recent literature proves that age is an important prognostic factor with OS being 
longer in patients who are younger at the time of diagnosis, in contradiction to older 
studies which failed to show any meaningful correlation between age and prognosis 
[9, 11–14]. Although gender has not been commonly thought to be a factor affecting 
prognosis, a study by Tugcu et al. has interestingly noted that male gender was a 
factor according better prognosis.
3.2 Timing of second surgery
Studies have shown that survival is not affected by the time interval between 
initial diagnosis/surgery and repeat surgery [15, 16].
3.3 Performance score
Studies have reported that better performance score at the time of presentation 
(KPS ≥ 70) correlates strongly with a longer OS [14, 16–18]. Chang et al. [16, 18, 
19] documented that the most important factor affecting OS is KPS at the time of 
recurrence. Quick et al., on the same lines, have demonstrated that good statistical 
parallel exists between KPS score and OS in their series [20]. Moreover, Michaelsen 
et al. have reported that the ECOG Performance Status significantly affects the OS 
following therapy [13].
3.4 Molecular markers
The role of molecular markers in predicting/affecting survival in recurrent GB 
has been controversial. Studies have shown an association between loss of MGMT 
expression and survival in patients with GB. Although this correlation was con-
firmed to have a prognostic significance at the time of first surgery, Brandes et al. 
reported that MGMT methylation status has no particular place in the prediction 
of outcome following repeat surgery. Similarly, multiple authors have noted that 
MGMT status at the time of redo surgery in GB patients has no effect on OS or on 
SFR [21, 22]. Mutations of IDH1 and IDH2 are known to be suggestive of secondary 
GB and to confer favorable prognosis [23, 24]. This was confirmed by Hartmann 
et al. who reported longer OS in patients with IDH mutant tumors as compared to 
the IDH wild-type ones. On the contrary, Amelot et al. have reported comparable 
long term survival in patients with and without IDH1/2 mutation [25, 26].
3.5 Extent of resection
That a greater extent of resection (EOR) confers an obvious advantage in 
patients being treated for GB has been demonstrated by multiple studies. This has 
been more widely evaluated and concluded at the time of first surgery [27–32]. 
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It suffices to say that surgical resection of the tumor is still the most effective 
therapy in GB, leading to instant decompression and improvement in the efficacy of 
adjuvant radiation by reducing tumor bulk. An increase in survival by an average of 
5.5 months was noted by Quick et al. in patients in whom atleast 95% of tumor was 
excised. This benefit was noted irrespective of tumor size. However, it is not as clear 
if such an advantage is conferred again during operation for recurrence [20]. On 
inquiry into whether this same benefit holds true in cases of recurrent GB, Robin 
et al., in their review article found 16 studies reinforcing the role of EOR in patient 
survival.
According to Stupp et al. surgery (5ALA fluorescence guided complete tumor 
resection) [35] done at the time of noting disease progression, along with additional 
chemotherapy (Temozolamide) and radiotherapy improved the average patient 
survival to more than 14 months. It was thereby suggested that, in patients where 
surgery for tumor recurrence is deemed prudent, Maximal Safe Resection of the GB 
should be aimed for [33].
The next logical question that arises would be the role of such ambitious surgery 
in further recurrences after the second operation. In a series of 578 primary GB 
patients were studied with reference to the number of repeat surgeries undertaken, 
Chaichana et al. concluded that patients who underwent multiple resections had 
better median survival than those who had single time surgery. The 15 patients 
in this study who underwent resection four times had a median survival of 
26.6 months compared to those who were operated once (354 patients), twice (168 
patients) and thrice (41 cases). These patients were found to have a median survival 
of 6.8, 15.5, 22.4 respectively [9].
Bloch et al. also conducted a valuable study on results of multiple resections in 
107 patients by four-way subgroup analysis after noting EORs during both first and 
second surgery. Whether the initial as well as subsequent surgery achieved Gross 
Total Resection (GTR) or Sub Total Resection (STR) of the tumor was made note 
of. Patients were then categorized into four resection groups: GTR/GTR, GTR/
STR, STR/GTR, and, STR/STR. On follow up, the study established that a survival 
advantage was conferred by performing complete tumor resection during both 
initial surgery as well as second surgery for recurrence of GB [31].
A series by Oppenlander and colleagues also confirms the advantage conferred 
by increased EOR in patients operated for rGB. A survival advantage was observed 
with even 80% resection of tumor volume. The OS for the entire cohort studied was 
19.0 months while median survival on Kaplan-Meier curves showed survival upto 
20 months and even 30 months when EOR was greater than 81 and 97%, respec-
tively. Multivariate analysis identified EOR, age, and KPS as independent predictors 
of survival [30].
Of particular interest is a study by Sanai et al. where in cases when a more com-
plete resection was deemed imprudent due to the tumor being located in eloquent 
brain, more limited resection (78% EOR) of the contrast enhancing lesion did cor-
respond to a survival benefit that was of significance statistically [4]. Despite being 
largely based on class II to III evidence, surgically reducing the amount of residual 
tumor does translate to longer PFS and better OS.
4.  Survival following reoperation for recurrent or progressive 
glioblastoma
With the advancement of refinement in surgical techniques and in nonsurgi-
cal adjunctive therapies, our understanding of the impact of surgery on survival 
in both newly diagnosed and recurrent GB increases. As elaborated so far, varied 
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studies have come to the common conclusion that a survival benefit is accorded by 
surgery, especially by the maximization of EOR, not only in newly diagnosed GB, 
but also in recurrent cases [9, 11, 16, 20, 34].
A detailed review of relevant literature by Ryken et al. suggests that reoperation 
adds about 8 or 9 months to the OS in select patients, without the added burden of 
significant morbidity. This positive outcome is especially observed in patients with 
age less than or equal to 50, KPS scores equal to or greater than 60 or 70 as well as 
favorable tumor location [36].
It can now be safely said that the most effective therapy in recurrent GB is surgi-
cal resection as it improves the efficacy of radiotherapy. Patient selection should 
take into consideration the so far observed positive prognostic factors and maximal 
safe tumor volume resection should be the surgical goal [33] in those patients who 
are candidates to second surgery.
5. Complications
Although surgery logically aims at maximal cytoreduction, the safety of this 
goal is compromised by factors such as highly infiltrative nature of tumor, eloquent, 
deep seated/periventricular location, advanced age and/or coexistence of comor-
bidities. A multicenter retrospective study documented a 2–4% increase in the rate 
of neurological and non-neurological complications in repeat surgery when com-
pared with initial surgery [37].
Following surgery for rGB, mortality rate has been shown to lie in the range of 
0–11% with morbidity rate varying from 13 to 69%, leaving a significant number of 
rGB patients in a condition that precludes administration of adjuvant therapy [19]. 
This risk, therefore, appeared to nullify the survival benefit of reoperation at recur-
rence when compared with patients of recurrence who received no treatment at all. 
Hence, the importance of safer surgery avoiding morbidity as well as judiciousness 
in decision making cannot be overstated.
6. Conclusions
The available literature suggests a higher OS in selected patients who were 
managed with repeat excision of tumor at the time of recurrence of Glioblastoma. 
Although a debate remains open regarding the benefit of such excision, a clear 
trend in its favor has become more evident. The decision of undertaking surgery 
for rGB should be individualized and should surely be considered in patients with a 
favorable functional score at the time of presentation with recurrent disease as well 
as favorable preoperative neurological and radiological characteristics. The goal of 
such repeat surgery should be the resolution of symptoms, stabilization or improve-
ment in QoL, increase in the time to further progression and reduction in require-
ment of steroid therapy. There is also the additional advantage of the possibility 
to offer intracavitary adjunctive therapy as well as an improved response to other 
adjunctive therapies [36]. As is customary to state, the actual value of such repeat 
surgery in comparison with systemic treatments and the effect of each on patient 
QoL and survical remains a topic for further prospective, randomized trials.
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